UNSPSC 51413505: Nitrendipine

This classification denotes a calcium channel blocker with the molecular formula C18H20N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9B627AW319, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester but generally known as nitrendipine, which bears US NIH Compound Identifier 4507. European Medicines Agency schedules Nitrendipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09320MIG.

UNSPSC 51413505 Nitrendipine is a Commodity code covering pharmaceutical products, specifically advanced cardiac and emergency medications for use by state and local public agencies. State and local governments procure these medications primarily for emergency medical services and public health programs, with recent activity showing purchases of specific injectable formulations and generic multi-source pharmaceuticals distributed through authorized wholesalers to fire rescue departments, health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions.

The issuing bodies soliciting under this code include city purchasing departments (City of Tampa), state health and human services commissions (Texas HHS Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon). Recent opportunities span Florida, Texas, and the Upper Midwest. The City of Tampa issued an IFB (Bid No. 26-P-00188) posted April 24, 2026, with a due date of April 8, 2026, for advanced life support medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem totaling an estimated contract value of $40,000, with a one-year term plus renewal options and a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities, requiring vendors to work through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with awards effective July 1, 2026, and a two-year contract term. The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs, signaling early-stage interest in alternative pharmaceutical sourcing models prior to formal RFP issuance.